188 related articles for article (PubMed ID: 293141)
21. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
[TBL] [Abstract][Full Text] [Related]
22. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
[TBL] [Abstract][Full Text] [Related]
23. Nabilone: an alternative antiemetic for cancer chemotherapy.
Dalzell AM; Bartlett H; Lilleyman JS
Arch Dis Child; 1986 May; 61(5):502-5. PubMed ID: 3013104
[TBL] [Abstract][Full Text] [Related]
24. [Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Güller R; Reichlin B; Jost G
Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1352-7. PubMed ID: 8765377
[TBL] [Abstract][Full Text] [Related]
25. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
26. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
27. Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy.
Ungerleider JT; Andrysiak TA; Fairbanks LA; Tesler AS; Parker RG
Radiology; 1984 Feb; 150(2):598-9. PubMed ID: 6318262
[TBL] [Abstract][Full Text] [Related]
28. The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
van den Berg AA
Anaesth Intensive Care; 1996 Oct; 24(5):538-45. PubMed ID: 8909662
[TBL] [Abstract][Full Text] [Related]
29. Effect of nabilone on nausea and vomiting after total abdominal hysterectomy.
Lewis IH; Campbell DN; Barrowcliffe MP
Br J Anaesth; 1994 Aug; 73(2):244-6. PubMed ID: 7917745
[TBL] [Abstract][Full Text] [Related]
30. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
[TBL] [Abstract][Full Text] [Related]
31. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
[TBL] [Abstract][Full Text] [Related]
32. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Poon RT; Chow LW
Br J Cancer; 1998 May; 77(10):1683-5. PubMed ID: 9635849
[TBL] [Abstract][Full Text] [Related]
33. A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty.
van den Berg AA
Can J Anaesth; 1996 Sep; 43(9):939-45. PubMed ID: 8874912
[TBL] [Abstract][Full Text] [Related]
34. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
35. Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters.
Havsteen H; Kjaer M
Anticancer Drugs; 1991 Dec; 2(6):571-9. PubMed ID: 1806034
[TBL] [Abstract][Full Text] [Related]
36. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues.
Carey MP; Burish TG; Brenner DE
Ann Intern Med; 1983 Jul; 99(1):106-14. PubMed ID: 6305249
[TBL] [Abstract][Full Text] [Related]
37. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study.
Sweet DL; Miller NJ; Weddington W; Senay E; Sushelsky L
J Clin Pharmacol; 1981; 21(S1):70S-75S. PubMed ID: 6271845
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences.
Moerman I; Franck P; Camu F
Acta Anaesthesiol Belg; 1995; 46(3-4):127-32. PubMed ID: 8669218
[TBL] [Abstract][Full Text] [Related]
39. delta 9-tetrahydrocannabinol in clinical oncology.
Poster DS; Penta JS; Bruno S; Macdonald JS
JAMA; 1981 May 22-29; 245(20):2047-51. PubMed ID: 6262541
[TBL] [Abstract][Full Text] [Related]
40. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
